HERS Protocol 6 — Hepatic Encephalopathy Recovery & Support
Post-TIPS Hepatic EncephalopathyManaging HE After Transjugular Intrahepatic Portosystemic Shunt Placement
← Back to main protocol
This protocol is specifically for patients who have developed hepatic encephalopathy following a TIPS (transjugular intrahepatic portosystemic shunt) procedure. The core HE management stack applies, but post-TIPS HE has specific features — including its mechanism, likelihood of being chronic, and the unique option of shunt revision — that deserve a dedicated discussion. Not a replacement for medical care.
⚡ What's Different After TIPS
Post-TIPS HE is caused by a fundamentally different mechanism than HE in cirrhosis alone:
- The shunt bypasses the liver directly. In portal hypertension, blood backs up in the portal venous system. TIPS creates a connection between the portal and hepatic veins, relieving the pressure — but also allowing portal blood (containing gut-derived ammonia) to bypass the liver entirely and enter the systemic circulation unfiltered.
- HE post-TIPS is more persistent. In cirrhosis without TIPS, some portal blood still passes through residual liver tissue. With a functioning TIPS, a significant fraction of portal blood perpetually bypasses whatever functional liver remains.
- Rifaximin is more commonly covered in post-TIPS HE than in general cirrhosis HE — it is a recognized complication of a planned procedure and insurance coverage is more straightforward. Worth pursuing aggressively before assuming it's out of reach.
- Shunt revision or reduction is a real option for refractory post-TIPS HE — reducing the shunt diameter reduces the blood volume bypassing the liver. This is a procedural decision made by the interventional radiology or hepatology team, but patients and families should know it exists.
- Lactulose compliance is typically worse post-TIPS due to the volume and side effects — MiraLax substitution is especially relevant and practically important in this population.
Understanding the TIPS Procedure and Why HE Follows
TIPS is performed to treat two major complications of portal hypertension: refractory ascites (fluid buildup that doesn't respond to diuretics) and variceal bleeding (bleeding from enlarged esophageal or gastric veins). It is an effective procedure for both indications — but it trades one complication for another in roughly one-third of patients.
The mechanism is direct: blood containing ammonia absorbed from the gut normally flows through the portal vein and passes through the liver, where ammonia is extracted and converted to urea. After TIPS, a fraction of that blood flows through the shunt, bypassing hepatic ammonia clearance entirely. The larger the shunt diameter, the more blood bypasses the liver, and the greater the HE risk.
Post-TIPS HE therefore requires more aggressive and often more permanent ammonia management than standard cirrhosis HE — because the underlying mechanism (portosystemic shunting) is structural and intentional, not simply a function of liver cell loss.
Rifaximin Coverage — Push for This First
💊 Insurance Coverage for Rifaximin Post-TIPS
Post-TIPS HE is a recognized, procedure-specific complication. Insurance carriers are more likely to cover rifaximin for this indication than for general cirrhotic HE. If rifaximin was prescribed post-TIPS and was denied:
- Request a prior authorization with the specific ICD-10 code for post-procedural HE (K72.10 or the most current coding)
- Ask the prescribing interventional radiologist or hepatologist to document post-TIPS HE specifically in the authorization letter
- Appeal denials — post-TIPS HE is a documented, guideline-recognized indication and denial appeals succeed at higher rates with documented procedural context
- GoodRx and Salix PAP remain fallback options (salix.com/therapeutic-areas/patient-focus/)
This protocol exists for cases where rifaximin remains unaffordable after all of the above. It is not an argument against pursuing rifaximin first — rifaximin is especially well-supported for post-TIPS HE specifically.
The Core Stack — Same Foundation, Higher Stakes
Bowel Management — Critical
MiraLax (Polyethylene Glycol 3350)
1 capful daily — titrate to 2–3 soft, formed stools per day. Given the persistent nature of post-TIPS ammonia exposure, consistent daily bowel management is non-negotiable.
The faster ammonia transits through the gut, the less time it has to be absorbed into portal blood — and from there, straight to the systemic circulation via the shunt. Every hour of delayed transit counts more post-TIPS because the normal hepatic ammonia extraction step has been partially removed from the circuit. This is the most mechanistically direct intervention available at home. MiraLax substitution for lactulose is especially practical here — lactulose compliance post-TIPS is poor due to side effects, and MiraLax achieves the same goal with dramatically better tolerability.
Core Ammonia Reduction — Begin Day One
LOLA (L-Ornithine L-Aspartate)
Start 6g/day (3g morning, 3g evening). Titrate over week one to 18g/day (6g three times daily) as tolerated.
LOLA supports whatever residual urea cycle capacity remains in the liver tissue that is still receiving blood flow. Post-TIPS, a fraction of portal blood still passes through the liver (the shunt is partial, not complete) — and LOLA maximizes the ammonia clearance efficiency of that fraction. It is arguably more important post-TIPS than in standard cirrhosis for this reason. Start immediately post-discharge. (Goh et al., Cochrane, 2018.)
Sourcing: BulkSupplements.com — pharmaceutical-grade LOLA powder, COA available, 1kg quantity. Digital milligram scale essential.
Gut Microbiome — Prebiotic
Sunfiber (Partially Hydrolyzed Guar Gum)
Per label — mixes invisibly into any drink
Reducing the ammonia-producing capacity of gut bacteria reduces the ammonia load entering the portal system in the first place — the point of origin that feeds the shunt. PHGG supports this at the source. Available from BulkSupplements.
Gut Microbiome — Probiotic
Visbiome (or quality Lactobacillus-dominant probiotic)
10–50 billion CFU once daily
Post-TIPS patients have demonstrated microbiome disruption that worsens HE outcomes. Probiotics represent one of the few interventions targeting ammonia production at its source — the gut bacteria. Visbiome has the most validated data for HE specifically. Sunfiber + probiotics together create both the nutritional substrate and the bacterial population for favorable microbiome shift.
Protein Timing — Non-Negotiable
Casein (evening) + Protein every 3–4 hours (daytime)
Total target: 1.2–1.5g/kg/day. BCAAs 12–20g/day evening. Absolutely no fasting beyond 4 hours.
Sarcopenia is extremely common in cirrhotic TIPS patients — the disease that leads to TIPS placement typically involves significant muscle loss. Skeletal muscle is itself an ammonia-clearing organ (via the glutamine synthetase pathway) and its loss directly worsens HE. Protecting and rebuilding muscle mass is a genuine HE management intervention in post-TIPS patients, not just a nutritional goal. BCAA supplementation has specific evidence in TIPS patients for improving both muscle mass and HE outcomes.
Urea Cycle Cofactor
Zinc (gluconate or bisglycinate)
25mg daily
Zinc deficiency is uniformly present in advanced cirrhosis and directly impairs the residual urea cycle capacity that LOLA is trying to support. Zinc repletion is supported by specific evidence in post-TIPS patients in several series. Available from BulkSupplements as gluconate powder.
Neuroprotective Support
Acetyl-L-Carnitine (ALCAR)
2g twice daily (4g/day)
ALCAR's blood-brain barrier penetration and ammonia-lowering properties are applicable regardless of HE cause. Carnitine deficiency is common in advanced cirrhosis and particularly relevant in the context of sarcopenia. Cognitive recovery support in the post-TIPS period can be prolonged; ALCAR provides a consistent neuroprotective element during that window.
When to Ask About Shunt Revision
If HE is severe, persistent, and unresponsive to maximal medical management (rifaximin + lactulose or the alternative protocol + dietary adherence), shunt revision or reduction is a real option that should be raised with the interventional radiology or hepatology team.
What shunt revision involves: A second procedure in which the TIPS stent diameter is reduced (typically from 10–12mm to 8mm) or the shunt is partially occluded with a plug or covered stent modification. This reduces the volume of blood bypassing the liver, trading some degree of HE improvement against the risk of portal hypertension symptoms (ascites, varices) recurring.
Who is a candidate: Patients with refractory HE that has not responded to full medical management and significantly impairs quality of life. The risk-benefit calculation weighs HE severity against portal hypertension recurrence risk.
How to raise it: "We have been managing post-TIPS HE with [protocol], and it remains significantly impacting quality of life. I'd like to discuss whether shunt diameter reduction or occlusion is appropriate to consider at this point."
When not to pursue it: If the TIPS was placed for refractory variceal bleeding and the bleeding risk remains high, reducing shunt flow may be dangerous. This requires careful case-by-case assessment.
Who is a candidate: Patients with refractory HE that has not responded to full medical management and significantly impairs quality of life. The risk-benefit calculation weighs HE severity against portal hypertension recurrence risk.
How to raise it: "We have been managing post-TIPS HE with [protocol], and it remains significantly impacting quality of life. I'd like to discuss whether shunt diameter reduction or occlusion is appropriate to consider at this point."
When not to pursue it: If the TIPS was placed for refractory variceal bleeding and the bleeding risk remains high, reducing shunt flow may be dangerous. This requires careful case-by-case assessment.
Daily Timing
Morning — with breakfast
Thiamine 100–300mg · B-50 Complex · Vitamin D3 + K2 · MiraLax · LOLA 6g · Sunfiber · Zinc 25mg · Probiotic/Visbiome
Midday — with lunch
LOLA 6g · Protein source · No 4-hour fast — the ammonia exposure is ongoing and structural; frequency of eating is a meaningful counter-measure
Evening — with dinner / before bed
LOLA 6g · BCAAs 12–20g · ALCAR 2g · Casein protein · Magnesium Glycinate 400mg
Throughout the Day
Water consistently · Electrolytes daily · Avoid sedatives, benzodiazepines, antihistamines — all worsen HE in a system that already has a structural portosystemic shunt
Diet
- Protein preference: Vegetable/dairy → eggs/fish → poultry → red meat last. 1.2–1.5g/kg/day total. Small frequent meals are especially important post-TIPS — 4–6 per day, no gap beyond 4 hours.
- No added salt — post-TIPS patients often have underlying ascites that motivated the procedure. Sodium control remains important to prevent ascites recurrence if the shunt effect wanes.
- No added sugar — reduces hepatic burden on whatever functional tissue remains
- No alcohol
- Plain unsweetened yogurt, eggs, bananas, avocado, sweet potato — potassium and magnesium food sources
- Mediterranean dietary pattern is a reasonable framework for this population
Monitoring
Asterixis Check (Hand Flap Test)
Arms extended, palms up, eyes closed, hold 15–20 seconds.
Watch for rhythmic involuntary flapping. In post-TIPS patients, asterixis may be a persistent feature during early weeks — the meaningful question is whether it is improving or worsening week over week. Any worsening trend warrants a call to the hepatology team. If asterixis was previously absent and returns, escalate promptly.
Daily Orientation Check
— What day is it? · Where are we? · What did you eat this morning? · Name of [family member]?
Watch for: sleep-wake reversal (awake at night, sleeping by day), day-over-day cognitive trend. In post-TIPS patients, monitoring is ongoing — this is not a short-term recovery but a chronic management situation for many patients.
Watch for: sleep-wake reversal (awake at night, sleeping by day), day-over-day cognitive trend. In post-TIPS patients, monitoring is ongoing — this is not a short-term recovery but a chronic management situation for many patients.
Bowel Movement Log
Target
2–3x/day, soft, formed
Too Little
0–1x or hard — increase MiraLax immediately
Too Much
4+ or watery — reduce MiraLax, increase electrolytes
Shunt Function Monitoring — for Radiology Follow-Up
TIPS patency is typically assessed by Doppler ultrasound at 1 month, 3 months, 6 months, and annually. This is the care team's tool, not a home monitoring task — but knowing it exists helps caregivers ensure appointments are kept.
A functioning (patent) TIPS continues to divert portal blood. A thrombosed or stenosed TIPS reduces the shunt effect — which may actually improve HE but worsen ascites and variceal risk. Clinical changes (improved HE but worsening ascites, or worsening HE after a period of stability) may reflect shunt patency changes and warrant early imaging.
Signs to Seek Care
- Asterixis worsening over consecutive days or returning after resolution
- Clear step-backward in orientation over 24–48 hours
- Fever — infection precipitates HE acutely and can also indicate shunt infection (rare but serious)
- GI bleeding — dark/tarry stools or vomiting blood. Variceal bleeding risk persists post-TIPS if the shunt is malfunctioning.
- Rapid increase in ascites after a period of stability — may indicate shunt stenosis or thrombosis
- Jaundice worsening
- Any loss of consciousness
- Severe muscle cramping or diarrhea >24h
Post-TIPS HE represents a structural challenge — the bypass is intentional and its ammonia consequences are the price of preventing other life-threatening complications. That trade-off is sometimes the right one. Managing the HE side of that equation well requires understanding what's actually happening mechanically, and using every available tool to compensate for what the liver can no longer do because of the shunt. This protocol is those tools.
Key References
Bai M et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Journal of Gastroenterology and Hepatology, 2011.
Goh ET et al. LOLA for HE in cirrhosis. Cochrane Database, 2018.
Rahimi RS et al. Lactulose vs PEG 3350 for Overt HE. JAMA Internal Medicine, 2014.
Riggio O et al. Pharmacological prophylaxis of hepatic encephalopathy after TIPS. Journal of Hepatology, 2005.
Amodio P et al. Nutritional management of HE: ISHEN guidelines. Hepatology, 2013.
EASL Clinical Practice Guidelines on nutrition in chronic liver disease. Journal of Hepatology, 2019.
Sanyal AJ et al. The North American Study for the Treatment of Refractory Ascites. Gastroenterology, 2003.